Does Rallies show 13F holders for VRCA?

Yes. Rallies tracks hedge fund and 13F ownership data for VRCA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VRCA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRCA. It does not provide personalized investment advice.

VRCA (Verrica Pharmaceuticals Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Verrica Pharmaceuticals Inc. Common Stock (VRCA) is a publicly traded Healthcare sector company. As of May 21, 2026, VRCA trades at $6.14 with a market cap of $100.84M and a P/E ratio of -5.37. VRCA moved +6.80% today. Year to date, VRCA is -32.13%; over the trailing twelve months it is -6.39%. Its 52-week range spans $3.28 to $17.49. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces VRCA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VRCA stock?

Hedge funds tracked by Rallies that own VRCA include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Verrica Pharmaceuticals Inc. Common Stock.

VRCA Key Metrics

Key financial metrics for VRCA
Metric	Value
Price	$6.14
Market Cap	$100.84M
P/E Ratio	-5.37
EPS	$-1.11
Dividend Yield	0.00%
52-Week High	$17.49
52-Week Low	$3.28
Volume	0
Avg Volume	0
Revenue (TTM)	$37.16M
Net Income	$-17.83M
Gross Margin	0.00%

Top Hedge Funds Holding VRCA

Exoduspoint Capital holds 186.13K shares of VRCA, changed +0.00% as of Sep 30, 2024.

Latest VRCA News

Verrica Q1 Revenue Jumps 60% to $6.7M, Net Loss Narrows — May 13, 2026
Verrica Posts $5M Q1 Revenue; YCANTH Units Rise 51.3% YoY and Launch in Japan — May 12, 2026
Verrica CEO to Present April 15 at Needham Conference, Spotlighting YCANTH® and VP-315 — Apr 6, 2026
Verrica Q4 Net Loss Narrows to $8.1M as YCANTH Rx Rollout Expands — Mar 11, 2026
Verrica Posts $35.6M 2025 Revenue, Grows YCANTH Sales 130% and Launches Phase 3 Trials — Mar 11, 2026

Recent VRCA Insider Trades

Rosenberg Noah L. bought 2.36K (~$10.00K) on Nov 25, 2025.
Kirby John J. bought 3.54K (~$15.00K) on Nov 25, 2025.
Zawitz David bought 10.00K (~$42.42K) on Nov 25, 2025.

VRCA Analyst Consensus

2 analysts cover VRCA: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.

Common questions about VRCA

Who owns VRCA stock?: Hedge funds tracked by Rallies that own VRCA include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Verrica Pharmaceuticals Inc. Common Stock.
Does Rallies show 13F holders for VRCA?: Yes. Rallies tracks hedge fund and 13F ownership data for VRCA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VRCA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRCA. It does not provide personalized investment advice.